Solaris Health

Solaris is a full-service medical communications agency with a highly experienced team.
Our services include:

Strategic communications consultancy
Developing a rationale for brand differentiation and assessing the options for effective brand communication

Opinion leader advocacy and engagement
Identifying and working with the key influencers to support your product

Publications strategy and planning
Raise brand profile, communicate evidence and clinical opinion, increase awareness both pre- and post-launch

Medical and patient education
Using the full spectrum of medical education opportunities to educate and empower patients and HCPs.
Raising disease awareness and highlighting brand value to effect change in prescribing patterns

Meetings management with extended reach
From congresses to virtual meetings, delivering your key messages and shaping the market

Creative communications
Award-winning creative and e-media solutions to differentiate and define your brand.
Digital platformsEffective and innovative e-delivery of your messages: online and mobile, social and experiential
http://blog.solarishealth.com/

• Abbvie
• Aimmune
• Almirall
• Ascensia
• BD
• Bio-Medical Research
• Desitin
• Ferring
• Flexyfoot
• Gedeon Richter
• GlaxoSmithKline
• Ipsen
• Meda
• PM Society
• Santhera
• Visufarma

Shaking up healthcare convention: Regenerative medicine and biosimilars impact health economy

See our Thought Leadership article reviewing pressures at both end of the cost spectrum and considering the likely impact on clinicians and patients.

Solaris Health and RJW & partners: Optimising Market Access

Team members at Solaris Health and RJW & partners (key healthcare agencies within the mission group) have combined on this best practice article exploring optimization of market access.

Solaris Health looks at the gene therapy revolution

Gene therapies are bringing new hope for many people with diseases caused by genetic disorders

Innovation in pharma: the highs and lows of the current healthcare economy

While the likely premium price of upcoming genetic and cell-based therapies challenges traditional NHS funding mechanisms, the continuing influx of biosmilars is driving down the cost of biologics. Marian Byrt looks at the challenges at both ends of the spectrum.

Grabbing your audience*

Highlighting one of our recent pieces of work - a powerful disease awareness film created in partnership with Watchable Films

Harnessing the power of core elements to optimise market access

This article by John Spoors and Anton Abrahams focuses on optimising market access – the RJW and Solaris Health teams operate across all major markets, where the principles set out here can be applied.